AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04358302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillsy
Description: The electronic pill bottle cap, Pillsy, and its accompanying software application provides reminders to take a scheduled dosage of medication via bottle cap alerts and smartphone push notifications, text messages, and/or automated phone calls. The Pillsy application records dosing dispense date and time when the user opens the bottle. During the first 2 weeks of the trial, the electronic notifications will be disabled to determine a baseline measure of adherence. Within 1 day after Visit 2, the electronic notifications will be turned on for all participants, resulting in a series of alerts (via electronic pill bottle cap alerts and smartphone push notifications, text message, and/or automated phone calls).~The electronic pill bottle cap, Pillsy, is a commercially available device marketed to consumers. The electronic pill bottle cap does not capture or store PHI. Quick tips on how to use Pillsy can be found at https://www.pillsy.com/instructions
Study NCT02471014 — intervention group
Intervention type: DRUG
Intervention: Pneumovax 23
Description: All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.
Study NCT01753570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: MP-424: 750mg every 8 hours (q8h) for 12 weeks
Study NCT01753570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV(24 weeks)
Description: RBV: 600 - 1000mg/day based on body weight for 24 weeks
Study NCT02471014 — intervention group
Intervention type: OTHER
Intervention: Blood tests
Description: All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.
Study NCT02471014 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: All participants will answer the following questionnaires:~UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.~Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.~Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.
Study NCT03030417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMP744
Description: Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand deoxyribonucleic acid (DNA) breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1-DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
Study NCT03030417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Anti-emetic for nausea or vomiting.
Study NCT04179188 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Classical Bariatric surgery (ring, Sleeve gastrectomy or Bypass)
Study NCT00808600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation training
Description: Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.
Study NCT00808600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensified anaerobic exercise training
Description: Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
Study NCT03030417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Persistent nausea or vomiting.
Study NCT03030417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Persistent nausea or vomiting.
Study NCT03030417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate
Description: Diphenoxylate hydrocholoride (HCL) 2.5 mg + Atropine Sulfate 0.025 mg/tablet for diarrhea.
Study NCT03030417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Antidiarrheal. 4mg by mouth (PO) after first unformed stool and 2mg PO every 2 hours as long as unformed stools continue. No more than 16mg during a 24-hour period.
Study NCT03030417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg intravenous (IV) for allergic reaction.
Study NCT03030417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steroid
Description: For allergic reaction at discretion of principal investigator.
Study NCT03030417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: For allergic reaction at discretion of principal investigator.
Study NCT02962661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Given standard of care
Study NCT00314275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Stenting
Description: Drug eluting stent
Study NCT00314275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor
Description: Drug eluting stent
Study NCT00623688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)
Description: Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
Study NCT00623688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airlife Sidestream High Efficiency Nebulizer
Description: Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
Study NCT02962661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given standard of care
Study NCT02962661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02962661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02962661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell Transplantation
Description: Given IV
Study NCT02962661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell Transplantation
Description: Given transendocardially
Study NCT02553057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation
Study NCT02491983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Study NCT02491983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Study NCT02491983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study NCT02491983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Study NCT04204707 — intervention group
Intervention type: OTHER
Intervention: PROMS
Description: Patient Reported Outcomes after different types of surgery for rectal endometriosis
Study NCT03546946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze-Contingent Music Reward Training
Description: Participants will hear their selected music track playing, dependent on their gaze location, when viewing a grid on neutral and negative faces.
Study NCT03546946 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Training
Description: Participants will hear their selected music track playing, regardless of their gaze location, when viewing a grid on neutral and negative faces.
Study NCT00808600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate aerobic exercise training
Description: Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
Study NCT05416034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the ATLAS 2025 exoskeleton at home
Description: Each participant will use the ATLAS 2025 exoskeleton at their homes, 5 days a week during a period of two months, for walking with the device and performing motor activities in 60 minutes duration sessions..
Study NCT00730366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfadoxine-pyrimethamine
Description: Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
Study NCT00730366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
Study NCT03638648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2500mg/m2/day, d1-d14, every 3 weeks a cycle for 8 cycles
Study NCT03638648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 2500mg/m2/day, d1-d14, every 3 weeks a cycle for 8 cycles
Study NCT04516291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vupanorsen
Description: Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
Study NCT02553421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivWatch Model 400
Description: The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
Study NCT00352612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin
Description: clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
Study NCT00990743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL040012
Description: Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
Study NCT00550017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epofolate
Description: Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses
Study NCT00530738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoplus
Description: i.v. fat emulsion for parenteral nutrition
Study NCT00530738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipofundin MCT
Description: i.V. fat emulsion for parenteral nutrition
Study NCT04783909 — intervention group
Intervention type: PROCEDURE
Intervention: Phacoemulsification cataract surgery
Description: All surgeries were performed using Infinity (Alcon Laboratories, Inc.) under topical anaesthesia by one surgeon through 2.2 mm incision in the upper corneal limbus. The hydroimplantation of IOL to the capsular bag was performed in all cases.
Study NCT00352612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cephalexin
Description: cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
Study NCT02827292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: A standard music with a standard volume as per the protocol will be played with headphones during the entire duration of the surgery starting from the point of induction to the time of extubation.~A proper silent operative room environment will be maintained.
Study NCT02827292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No music
Description: Silent Headphones (Without music) will be applied to the patient from the point of induction of anaesthesia to the time of extubation.
Study NCT02827292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery
Description: Patients will undergo Laparoscopic Surgery as per the set protocol
Study NCT00369577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Inhaled Placebo, single dose
Study NCT00369577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine 5 mg
Description: Inhaled Staccato Loxapine 5 mg, single dose
Study NCT00369577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine 10 mg
Description: Inhaled Staccato Loxapine 10 mg, single dose
Study NCT00684775 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Work Plus Naltrexone Contingency
Description: Vivitrol, an extended-release depot formulation of naltrexone, was used. Participants were offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) were randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the Work Plus Naltrexone Contingency condition earned access to working and earning salary by taking depot naltrexone injections once per month.
Study NCT01391663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.
Study NCT01391663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
Study NCT04516291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
Study NCT01278823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic roux en y gastric bypass operation
Description: roux en y gastric bypass operation
Study NCT02259491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuka Honey Dressing
Description: After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
Study NCT03077165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S42909 100 mg
Description: 50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Study NCT03077165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S42909 200 mg
Description: 50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Study NCT01278823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical management
Description: latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
Study NCT01238861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 2 mg
Description: EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
Study NCT03077165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S42909 400 mg
Description: 200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Study NCT03077165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S42909 800 mg
Description: 200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
Study NCT03077165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S42909 1200 mg
Description: 200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Study NCT03077165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
Study NCT01238861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 20 mg
Description: EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
Study NCT01238861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg
Description: EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
Study NCT01238861 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: EOS+ and EOS- participants received two placebo injections subcutaneously.
Study NCT02970838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured weight-loss program
Description: During the fasting phase, daily consumption consists of five sachets fully replacing normal food and corresponded to an energy content of 800 kcal. This fasting phase is followed by a four-week refeeding phase, during which regular food will be reintroduced and formula diet is gradually replaced until a daily total intake of 1200 kcal is reached. During the last five weeks of the program, energy intake is gradually increased to an individual level between 1200 kcal and 1500 kcal that allowed subjects to keep their weight stable.~Once a week participants visit the study center to monitor health status and taking part in supervised exercises and a nutritional and behavioral counseling.
Study NCT03126097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64155806 150 mg
Description: JNJ-64155806 150 mg (3\*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 \[JNJ-64155806 Alone Phase\] and on Days 60 to 66 \[JNJ-64155806 + COCP Coadministration Phase\].
Study NCT03126097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/drospirenone 0.02 mg/3 mg
Description: Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).
Study NCT03126097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COCP Placebo
Description: Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
Study NCT01932541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latuda (Lurasidone)
Description: Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
Study NCT01753570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN beta(24 weeks)
Description: IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks
Study NCT01391663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.
Study NCT03923894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Yeast Fermentation Freeze Dying Powder Extract
Description: Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
Study NCT03923894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2.07 g/day for 8 weeks.
Study NCT04311684 — intervention group
Intervention type: DEVICE
Intervention: hybrid Brillouin-Raman spectroscopy
Description: Combination of Brillouin and surface-enhanced Raman (SERS) spectroscopy for assessment of both visco-elastic (i.e. mechanical) and chemical characterization of urinary proteins at the same time from the same excitation laser source
Study NCT03946163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cinnamon capsules
Description: each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month